Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium

Susan J. Coker, J. Parratt, I. McA Ledingham, I. J. Zeitlin

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In many victims of sudden cardiac death, resulting from ventricular fibrillation, there is no post-mortem evidence of coronary thrombosis [7] and it is thought that spasm of the coronary arteries or reversal of such spasm may be the cause of the ventricular fibrillation. When coronary vasospasm is reversed, either spontaneously or by other means, arrhythmias are frequently observed when perfusion of the formerly ischaemic area of the myocardium is restored. These "reperfusion arrhythmias" are particularly severe and frequently fatal since they often progress to ventricular fibrillation. They also appear to be resistant to standard antiarrhythmic therapy [5] suggesting that their aetiology may vary from that of arrhythmias observed during myocardial ischaemia. We have reported previously [3] that thromboxane A2, a potent vasoconstrictor which promotes platelet aggregation, is released during acute myocardial ischaemia and that this release is related to the occurrence of early cardiac arrhythmias. In the present study we have extended our experiments in anaesthetized greyhounds to investigate whether thromboxane plays a role in the reperfusion arrhythmias that occur following the release of a 40 min coronary artery occlusion. Dazoxiben (UK-37, 248), a selective thromboxane synthetase inhibitor [6], markedly increased survival following coronary artery reperfusion suggesting that thromboxane is an important contributory factor in post-reperfusion ventricular fibrillation.

Original languageEnglish
Pages (from-to)483-485
Number of pages3
JournalJournal of Molecular and Cellular Cardiology
Volume14
Issue number8
DOIs
Publication statusPublished - 1982

Fingerprint

Thromboxanes
Ventricular Fibrillation
Reperfusion
Cardiac Arrhythmias
Myocardium
Coronary Vessels
Spasm
Myocardial Ischemia
Coronary Vasospasm
Thromboxane-A Synthase
Coronary Thrombosis
Myocardial Reperfusion
Thromboxane A2
Coronary Occlusion
Sudden Cardiac Death
Vasoconstrictor Agents
Platelet Aggregation
Perfusion
dazoxiben

Keywords

  • Dazoxiben
  • Reperfusion
  • Thromboxane
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium. / Coker, Susan J.; Parratt, J.; Ledingham, I. McA; Zeitlin, I. J.

In: Journal of Molecular and Cellular Cardiology, Vol. 14, No. 8, 1982, p. 483-485.

Research output: Contribution to journalArticle

@article{5124600c4fbf4709b9e4e39d6fcf2826,
title = "Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium",
abstract = "In many victims of sudden cardiac death, resulting from ventricular fibrillation, there is no post-mortem evidence of coronary thrombosis [7] and it is thought that spasm of the coronary arteries or reversal of such spasm may be the cause of the ventricular fibrillation. When coronary vasospasm is reversed, either spontaneously or by other means, arrhythmias are frequently observed when perfusion of the formerly ischaemic area of the myocardium is restored. These {"}reperfusion arrhythmias{"} are particularly severe and frequently fatal since they often progress to ventricular fibrillation. They also appear to be resistant to standard antiarrhythmic therapy [5] suggesting that their aetiology may vary from that of arrhythmias observed during myocardial ischaemia. We have reported previously [3] that thromboxane A2, a potent vasoconstrictor which promotes platelet aggregation, is released during acute myocardial ischaemia and that this release is related to the occurrence of early cardiac arrhythmias. In the present study we have extended our experiments in anaesthetized greyhounds to investigate whether thromboxane plays a role in the reperfusion arrhythmias that occur following the release of a 40 min coronary artery occlusion. Dazoxiben (UK-37, 248), a selective thromboxane synthetase inhibitor [6], markedly increased survival following coronary artery reperfusion suggesting that thromboxane is an important contributory factor in post-reperfusion ventricular fibrillation.",
keywords = "Dazoxiben, Reperfusion, Thromboxane, Ventricular fibrillation",
author = "Coker, {Susan J.} and J. Parratt and Ledingham, {I. McA} and Zeitlin, {I. J.}",
year = "1982",
doi = "10.1016/0022-2828(82)90156-0",
language = "English",
volume = "14",
pages = "483--485",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "8",

}

TY - JOUR

T1 - Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium

AU - Coker, Susan J.

AU - Parratt, J.

AU - Ledingham, I. McA

AU - Zeitlin, I. J.

PY - 1982

Y1 - 1982

N2 - In many victims of sudden cardiac death, resulting from ventricular fibrillation, there is no post-mortem evidence of coronary thrombosis [7] and it is thought that spasm of the coronary arteries or reversal of such spasm may be the cause of the ventricular fibrillation. When coronary vasospasm is reversed, either spontaneously or by other means, arrhythmias are frequently observed when perfusion of the formerly ischaemic area of the myocardium is restored. These "reperfusion arrhythmias" are particularly severe and frequently fatal since they often progress to ventricular fibrillation. They also appear to be resistant to standard antiarrhythmic therapy [5] suggesting that their aetiology may vary from that of arrhythmias observed during myocardial ischaemia. We have reported previously [3] that thromboxane A2, a potent vasoconstrictor which promotes platelet aggregation, is released during acute myocardial ischaemia and that this release is related to the occurrence of early cardiac arrhythmias. In the present study we have extended our experiments in anaesthetized greyhounds to investigate whether thromboxane plays a role in the reperfusion arrhythmias that occur following the release of a 40 min coronary artery occlusion. Dazoxiben (UK-37, 248), a selective thromboxane synthetase inhibitor [6], markedly increased survival following coronary artery reperfusion suggesting that thromboxane is an important contributory factor in post-reperfusion ventricular fibrillation.

AB - In many victims of sudden cardiac death, resulting from ventricular fibrillation, there is no post-mortem evidence of coronary thrombosis [7] and it is thought that spasm of the coronary arteries or reversal of such spasm may be the cause of the ventricular fibrillation. When coronary vasospasm is reversed, either spontaneously or by other means, arrhythmias are frequently observed when perfusion of the formerly ischaemic area of the myocardium is restored. These "reperfusion arrhythmias" are particularly severe and frequently fatal since they often progress to ventricular fibrillation. They also appear to be resistant to standard antiarrhythmic therapy [5] suggesting that their aetiology may vary from that of arrhythmias observed during myocardial ischaemia. We have reported previously [3] that thromboxane A2, a potent vasoconstrictor which promotes platelet aggregation, is released during acute myocardial ischaemia and that this release is related to the occurrence of early cardiac arrhythmias. In the present study we have extended our experiments in anaesthetized greyhounds to investigate whether thromboxane plays a role in the reperfusion arrhythmias that occur following the release of a 40 min coronary artery occlusion. Dazoxiben (UK-37, 248), a selective thromboxane synthetase inhibitor [6], markedly increased survival following coronary artery reperfusion suggesting that thromboxane is an important contributory factor in post-reperfusion ventricular fibrillation.

KW - Dazoxiben

KW - Reperfusion

KW - Thromboxane

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0019921253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019921253&partnerID=8YFLogxK

U2 - 10.1016/0022-2828(82)90156-0

DO - 10.1016/0022-2828(82)90156-0

M3 - Article

VL - 14

SP - 483

EP - 485

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 8

ER -